← Human Trials & Peer-Reviewed Studies
GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide
Plain-language guide to PMID 21209033 (2011): randomized controlled trial study of Glucagon and Calcitonin in 5000 subjects.
Key Facts
- PMID
- 21209033
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Hegedüs L et al. (5 authors)
- DOI
- 10.1210/jc.2010-2318
- Registered trial
- NCT00318422
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Glucagon and Calcitonin.
The aim of the study was to determine serum CT response over time to the GLP-1 receptor agonist liraglutide in subjects with type 2 diabetes mellitus or nondiabetic obese subjects.
Why It Was Studied
Serum calcitonin (CT) is a well-accepted marker of C-cell proliferation, particularly in medullary thyroid carcinoma.
There are no longitudinal studies measuring CT in humans without medullary thyroid carcinoma or a family history of medullary thyroid carcinoma and no published studies on the effect of GLP-1 receptor agonists on human serum CT concentrations.
Who Took Part
The study group was 5000 subjects.
PubMed indexes the participants as adults and middle-aged adults, both men and women.
Unstimulated serum CT concentrations were measured at 3-month intervals for no more than 2 yr in a series of trials in over 5000 subjects receiving liraglutide or control therapy.
How the Study Was Run
The design is described as randomized.
The subjects were allocated by chance, so the Glucagon group and the comparison group should start out alike.
What Was Measured
There are no longitudinal studies measuring CT in humans without medullary thyroid carcinoma or a family history of medullary thyroid carcinoma and no published studies on the effect of GLP-1 receptor agonists on human serum CT concentrations.
Topics PubMed links to this paper include Calcitonin, Diabetes Complications, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor, Hypoglycemic Agents and Liraglutide.
What This Means in Plain Language
The paper is a randomized study of Glucagon and Calcitonin in 5000 subjects.
With several hundred people or more, it is a fairly large study for this kind of research.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2011 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Glucagon compound page and the Calcitonin compound page.
Our Notes on the Compounds
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Calcitonin: A 32-amino-acid hormone that lowers blood calcium; salmon calcitonin (Miacalcin) has been used for Paget disease and osteoporosis.
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.